- Home
- CHGA vs RDHL Comparison
CHGA vs RDHL Comparison
Compare CHGA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHGA | RDHL |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.3M |
| IPO Year | 2015 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CHGA | RDHL |
|---|---|---|
| Price | $1.41 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.4K | ★ 846.6K |
| Earning Date | 11-13-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.44 |
| 52 Week High | $3.02 | $1.90 |
Technical Indicators
Market Signals| Indicator | CHGA | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 43.96 |
| Support Level | $0.25 | $0.44 |
| Resistance Level | $2.54 | $0.71 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 0.83 | 24.99 |
Price Performance
Historical ComparisonAbout CHGA Change Agents Corporation Common Stock
Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.